IBM Still Looks 35% Off Fair Value-But Weak Checks Keep the Discount Alive

IBM still looks undervalued, but the quarter did not simplify the case

IBM is cheap in the obvious way, not in the clean way investors want. Even after the stock sold off sharply, the model still points to $285.99 fair value against a roughly $211.20 market price, or about 35% upside. That leaves room for value investors to stay interested, but the latest quarter did not give them a simple reason to rush in.

The market is pricing execution fear, not just valuation

IBM issued an earnings warning last week, then reported $17.16 billion of revenue versus $17.58 billion expected and $2.93 adjusted EPS versus $2.97 expected. Management also kept full-year guidance at 4% to 5% constant-currency revenue growth, after previously pointing to just above 5% growth. That is why investors are focusing on the miss and the softer tone rather than the long-term upside.

Why the discount persists

This looks more like a trust discount than evidence of a broken business. Bulls can still point to IBM's positioning across software, infrastructure, and consulting. Bears focus on large enterprise license agreement timing and mainframe-linked purchasing behavior, which makes the earnings path look lumpier than investors prefer. If the next few updates show the slowdown was temporary rather than structural, sentiment could improve quickly.

The weak spots were concentrated, but the core business still looked intact

IBM's valuation discount still looks more like punishment for inconsistency than proof of lasting damage. The quarter softened where timing matters most: infrastructure revenue down 7 percent, with management citing a shortfall in Z performance and the associated software stack, while outside analysis pointed to large enterprise license agreement timing and mainframe-linked purchasing behavior. But the rest of the business did not break in the same way.

Where investor patience wore thin

The pressure was concentrated. Overall revenue still grew 1%, and software revenue grew 5%. Still, consulting revenue was flat, up just 1% at constant currency, even though consulting signings growth was 6%. That gap is frustrating for investors: demand appears present, but conversion into recognized revenue was slower than hoped. Once the market sees that kind of delay, it is quick to treat a quarter-specific issue as a pattern.

What held up better

The more durable parts of the story still looked healthy. Data revenue grew 18%, Red Hat growth accelerated 11% sequentially, annual recurring revenue rose 8% year over year, and recurring software accounted for 80% of annual software revenue. That mix matters because it suggests the parts of the business customers pay for over multiple years continued to expand.

The key question now is whether IBM can turn delayed mainframe and ELA activity into recognized revenue while the recurring base keeps compounding. If software growth softens, or Red Hat and data momentum fade, the thesis would look weaker. For now, the discount looks more aligned with execution inconsistency than with fundamental damage.

A rerating is plausible, but it still needs proof

IBM has already rebounded 17.89% over the past 90 days, which suggests sentiment is improving. Still, the stock does not trade like a fully trusted growth compounder. It also continues to generate strong cash: IBM produced $7.8 billion of operating cash flow in the first half, along with $4.8 billion of free cash flow and $3.2 billion of dividends paid through midyear. That cash profile gives the company room to absorb messy timing without forcing investors to assume the earnings base is fragile.

What could drive a rerating

A rerating does not require a heroic quarter. It requires evidence that the weak spots were temporary and that the recurring core can carry more of the story. The clearest positive signals would be:

• Delayed mainframe and ELA deals converting into reported revenue.
• Consulting signings starting to show up more clearly in revenue.
• Continued strength in recurring software, Red Hat, and data.

What would weaken the thesis

The discount starts to look structural rather than temporary if demand is genuinely softer, not just delayed. The clearest warning signs would be slower software growth, weaker Red Hat or data momentum, or a less stable recurring revenue base.

For now, the stance remains cautiously constructive. The cash engine keeps the thesis supportable, but the stock likely needs a cleaner execution read-through before the market fully closes the gap to fair value.